3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Phase 1
1
Status
Recruiting
2
Terminated
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
1
Other neoplasm
1
Gynecologic
1
CNS
1
Conditions
Neoplasms
2
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Precancerous Conditions
1
Neuroblastoma
1
Neoplasms by Site
1
Lung Neoplasms
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Interventions
pembrolizumab
1270
Specimen Handling
870
Carboplatin
831
Magnetic Resonance Spectroscopy
808
Cyclophosphamide
802
Cisplatin
728
Nivolumab
658
Paclitaxel
631
Radiotherapy
573
Gemcitabine
572
Biopsy
529
Bevacizumab
475
Dexamethasone
440
fludarabine
407
Docetaxel
378
venetoclax
370
Oxaliplatin
365
Capecitabine
356
Fluorouracil
354
atezolizumab
341
durvalumab
334
Rituximab
332
Doxorubicin
316
Radiosurgery
309
Pemetrexed
305
Drug Therapy
302
Ipilimumab
294
Standard of Care
293
Etoposide
285
Radiation
279
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
Pregnancy Tests
×
1 year
×
Clear all
NCT06620835
2026-04-29
OPTALK
Groupe Francais De Pneumo-Cancerologie
Phase 2
Recruiting
45 enrolled
NCT02780128
2026-03-10
NEPENTHE
Children's Hospital of Philadelphia
Phase 1
Terminated
66 enrolled
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled